MAPT and Alzheimer disease: Our observation of low neocortical pTau neuropathology and low neocortical NP-Tau in the PRIME LTE Patient compared to the reference cohort of HIGH AD cases notably parallels the reduction in the progression of Tau PET, CSF pTau and plasma pTau181 biomarkers in Phase 3 ENGAGE and EMERGE studies [6].